RESUMEN
We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.
Asunto(s)
Fármacos Anti-VIH , Anticuerpos Monoclonales , Infecciones por VIH , Humanos , Foscarnet/uso terapéutico , VIH-2 , Fármacos Anti-VIH/uso terapéutico , Terapia Recuperativa , Infecciones por VIH/tratamiento farmacológicoRESUMEN
OBJECTIVES: HIV pre-exposure prophylaxis (PrEP) is effective in preventing HIV, but some seroconversions occur due to poor adherence or PrEP discontinuation. Our objective was to estimate the incidence of PrEP discontinuation and describe the reasons and factors associated with discontinuations. METHODS: A retrospective cohort was conducted in three French hospitals between January 2016 and June 2022. PrEP users who attended at least twice within 6â months during study period were included and followed up until December 2022. The incidence rate of PrEP discontinuation was estimated by censoring lost to follow up individuals. Factors associated with PrEP discontinuations were identified using a multivariate Cox model. RESULTS: A total of 2785 PrEP users were included, with 94% men and 5% transgender people. Median age was 35â years. By December 2022, 653 users had stopped PrEP (24%). The incidence rate was 10.8 PrEP discontinuations for 100 person-years (PY). The main causes of discontinuation were being in a stable relationship (32%), and not judging the treatment useful anymore (12%). Individuals who discontinued PrEP were younger [<29, HRâ=â1.45 (1.17-1.80)], and more likely to be women [HRâ=â2.44 (1.50-3.96)] or sex workers [HRâ=â1.53 (0.96-2.44)]. They were more likely to report PrEP side effects [HRâ=â2.25 (1.83-2.77)] or ≥2 sexually transmitted infections [HRâ=â1.87 (1.53-2.27)] during the last year. CONCLUSION: The incidence of PrEP discontinuations was quite low compared to rates observed in other cohorts. Users who stopped PrEP were sometimes still exposed to HIV, emphasizing the need for targeted interventions to prepare and support PrEP discontinuations and limit seroconversion risk.
Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , Profilaxis Pre-Exposición , Humanos , Francia/epidemiología , Femenino , Masculino , Adulto , Infecciones por VIH/prevención & control , Infecciones por VIH/epidemiología , Profilaxis Pre-Exposición/estadística & datos numéricos , Estudios Retrospectivos , Incidencia , Fármacos Anti-VIH/uso terapéutico , Fármacos Anti-VIH/administración & dosificación , Cumplimiento de la Medicación/estadística & datos numéricos , Persona de Mediana Edad , Adulto JovenRESUMEN
BackgroundSome migrant men who have sex with men (MSM) acquire HIV in France.AimsWe investigated, in migrant MSM receiving HIV care in France, the (i) rate of post-migration-HIV acquisition in France, (ii) delay between arrival and HIV acquisition and (iii) factors affecting HIV acquisition within 1 year after migration.MethodsThis cross-sectional study focused on ≥ 18-year-old MSM born outside France, receiving HIV care in the Paris region. Information on migration history, socioeconomic condition, sexual activity, and health was collected in May 2021-June 2022 through self-administered questionnaires and medical records. Post-migration-HIV-acquisition rate and delay between arrival in France and HIV acquisition were estimated from biographical data and CD4+ T-cell counts. Predictors of HIV acquisition within 1 year after migration were determined using logistic regression.ResultsOverall post-migration HIV-acquisition rate was 61.7% (715/1,159; 95%CI: 61.2-62.2), ranging from 40.5% (95%CI: 39.6-41.6) to 85.4% (95%CI: 83.9-86.0) in participants from Latin America and North Africa. Among post-migration-HIV acquisitions, those within 1 year after migration represented 13.1% overall (95%CI: 11.6-14.6), being highest in participants from sub-Saharan Africa (25%; 95%CI: 21.5-28.3). Participants ≥ 15-years old at migration, with post-migration-acquired HIV, had a 7.5-year median interval from arrival in France to HIV acquisition (interquartile range (IQR): 3.50-14.75). Older age at arrival, region of origin (sub-Saharan Africa and Asia), degree of social disadvantage and numbers of sexual partners were independently associated with acquiring HIV within 1 year in France.ConclusionOur findings may guide HIV prevention policies for most vulnerable migrants to Europe.
Asunto(s)
Infecciones por VIH , Minorías Sexuales y de Género , Migrantes , Masculino , Humanos , Adolescente , Infecciones por VIH/diagnóstico , Infecciones por VIH/epidemiología , Infecciones por VIH/prevención & control , Homosexualidad Masculina , Paris/epidemiología , Estudios Transversales , Conducta Sexual , Francia/epidemiologíaRESUMEN
UPDATES IN HIV INFECTION THERAPEUTICS. Human immunodeficiency virus (HIV) is still a world public health challenge, with constant therapeutic innovations involved. Very efficient treatments, with a high impact on HIV morbimortality, are now used in routine. Therefore, the new challenges focus on transmission prevention, side effects reduction and quality-of-life improvement. Therapeutic news in the management of patients living with HIV is varied: new molecules, changes in treatment modalities, prevention .
ACTUALITÉS THÉRAPEUTIQUES DANS L'INFECTION PAR LE VIH. L'infection par le virus de l'immunodéficience humaine (VIH) reste en France et dans le monde un problème de santé publique et fait l'objet d'innovations thérapeutiques constantes. Après la réussite des traitements qui ont fait la preuve de leur efficacité en matière de morbi-mortalité liée au VIH, les nouveaux défis sont aujourd'hui tournés vers la prévention de la transmission, la réduction des effets indésirables et l'amélioration de la qualité de vie des patients. Les actualités thérapeutiques dans la prise en charge des patients vivant avec le VIH sont variées : nouvelles molécules, évolution des modalités de traitement, prévention .
Asunto(s)
Infecciones por VIH , Humanos , Infecciones por VIH/tratamiento farmacológicoRESUMEN
BACKGROUND: Increased rates of sexually transmitted infections (STIs) are reported among men who have sex with men (MSM) and new interventions are needed. We aimed to assess whether post-exposure prophylaxis (PEP) with doxycycline could reduce the incidence of chlamydia or syphilis (or both) and whether the meningococcal group B vaccine (4CMenB) could reduce the incidence of gonorrhoea in this population. METHODS: ANRS 174 DOXYVAC is a multicentre, open-label, randomised trial with a 2â×â2 factorial design conducted at ten hospital sites in Paris, France. Eligible participants were MSM aged 18 years or older, HIV negative, had a history of bacterial STIs within the 12 months before enrolment, and who were already included in the ANRS PREVENIR study (a cohort of MSM using pre-exposure prophylaxis with tenofovir and emtricitabine for HIV prevention). Participants were randomly assigned (2:1) to doxycycline PEP (two pills of 100 mg each orally within 72 h after condomless sex, with no more than three doses of 200 mg per week) or no PEP groups and were also randomly assigned (1:1) to the 4CMenB vaccine (GlaxoSmithKline, Paris, France; two intramuscular injections at enrolment and at 2 months) or no vaccine groups, using a computer-generated randomisation list with a permuted fixed block size of four. Follow-up occurred for at least 12 months (with visits every 3 months) up to 24 months. The coprimary outcomes were the risk of a first episode of chlamydia or syphilis (or both) after the enrolment visit at baseline for the doxycycline intervention and the risk of a first episode of gonorrhoea starting at month 3 (ie, 1 month after the second vaccine dose) for the vaccine intervention, analysed in the modified intention-to-treat population (defined as all randomly assigned participants who had at least one follow-up visit). This trial is registered with ClinicalTrials.gov, NCT04597424 (ongoing). FINDINGS: Between Jan 19, 2021, and Sept 19, 2022, 556 participants were randomly assigned. 545 (98%) participants were included in the modified intention-to-treat analysis for the doxycycline PEP and no PEP groups and 544 (98%) were included for the 4CMenB vaccine and no vaccine groups. The median follow-up was 14 months (IQR 9-18). The median age was 40 years (34-48) and all 545 participants were male. There was no interaction between the two interventions (p≥0·1) for the primary outcome. The incidence of a first episode of chlamydia or syphilis (or both) was 8·8 per 100 person-years (35 events in 362 participants) in the doxycycline PEP group and 53·2 per 100 person-years (80 events in 183 participants) in the no PEP group (adjusted hazard ratio [aHR] 0·17 [95% CI 0·12-0·26]; p<0·0001). The incidence of a first episode of gonorrhoea, starting from month 3 was 58·3 per 100 person-years (103 events in 274 participants) in the 4CmenB vaccine group and 77·1 per 100 person-years (122 events in 270 participants) in the no vaccine group (aHR 0·78 [95% CI 0·60-1·01]; p=0·061). There were no deaths during the study. One drug-related serious adverse event (fixed-drug eruption) occurred in the doxycycline PEP group. Six (2%) participants in the doxycycline group discontinued doxycycline PEP because of gastrointestinal adverse events. INTERPRETATION: Doxycycline PEP strongly reduced the incidence of chlamydia and syphilis in MSM, but we did not show efficacy of the 4CmenB vaccine for gonorrhoea. Doxycycline PEP should be assessed in other populations, such as heterosexual men and women, and its effect on antimicrobial resistance carefully monitored. FUNDING: ANRS Maladies Infectieuses Emergentes. TRANSLATION: For the French translation of the abstract see Supplementary Materials section.
RESUMEN
BACKGROUND: Cabotegravir + rilpivirine long-acting (CAB + RPV LA) dosed every 2 months (Q2M) is a complete regimen for the maintenance of HIV-1 virologic suppression. In this study, we report month 12 clinical outcomes in patient study participants (PSPs) in the CAB and RPV Implementation Study in European Locations (CARISEL) study. SETTING: CARISEL is a phase 3b implementation-effectiveness study. METHODS: CARISEL was designed as a 2-arm, unblinded study with centers randomized to either enhanced or standard implementation arms. For PSPs, this study is single arm, unblinded, and interventional; all PSPs switched from daily oral therapy to CAB + RPV LA dosed Q2M. The primary objective was to evaluate the perceived acceptability, appropriateness, and feasibility of CAB + RPV LA implementation for staff participants (presented separately). Clinical secondary endpoints assessed through month 12 included the proportion of PSPs with plasma HIV-1 RNA ≥50 and <50 copies/mL (Snapshot algorithm), incidence of confirmed virologic failure (CVF; 2 consecutive plasma HIV-1 RNA levels ≥200 copies/mL), adherence to injection visit windows, and safety and tolerability. RESULTS: Four hundred thirty PSPs were enrolled and treated; the mean age was 44 years (30% ≥50 years), 25% were women (sex at birth), and 22% were persons of color. At month 12, 87% (n = 373/430) of PSPs maintained HIV-1 RNA <50 copies/mL, with 0.7% (n = 3/430) having HIV-1 RNA ≥50 copies/mL. One PSP had CVF. The safety profile was consistent with previous findings. Overall, the results were similar between implementation arms. CONCLUSION: CAB + RPV LA Q2M was well tolerated and highly effective in maintaining virologic suppression with a low rate of virologic failure.
Asunto(s)
Fármacos Anti-VIH , Infecciones por VIH , VIH-1 , Piridonas , Rilpivirina , Humanos , Rilpivirina/uso terapéutico , Rilpivirina/administración & dosificación , Infecciones por VIH/tratamiento farmacológico , Femenino , Masculino , Piridonas/uso terapéutico , Fármacos Anti-VIH/uso terapéutico , Fármacos Anti-VIH/administración & dosificación , Adulto , Persona de Mediana Edad , VIH-1/efectos de los fármacos , VIH-1/genética , Europa (Continente) , Carga Viral/efectos de los fármacos , Resultado del Tratamiento , Quimioterapia Combinada , DicetopiperazinasRESUMEN
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified.
Asunto(s)
Infecciones Asintomáticas , COVID-19 , SARS-CoV-2 , Humanos , COVID-19/genética , COVID-19/inmunología , SARS-CoV-2/inmunología , Masculino , Femenino , Alelos , Antígenos HLA/genética , Persona de Mediana Edad , Adulto , Estudios Prospectivos , Anciano , Predisposición Genética a la EnfermedadRESUMEN
Context: Homeless individuals face exacerbated risks of infectious diseases, including sexually transmitted infections (STIs). Programs led by Community Health Workers (CHWs) have demonstrated potential to enhance healthcare access for marginalized groups such as homeless families. This study aims to evaluate the feasibility and effectiveness of a novel CHW-based outreach program addressing sexual health issues among individuals residing in homeless hostels. Methods: Twelve social homeless hostels in the greater Paris region were selected as program implementation sites. An outreach program was developed consisting of two interventions: sexual health workshops and STI screening sessions (HIV and hepatitis B and C) accompanied by individual interviews, both conducted by CHWs within each hostel over an 8-week period and scheduled weekly. Feasibility, participation and engagement were evaluated using complementary methods including qualitative field observations, semi-structured interviews and focus groups with CHWs, satisfaction questionnaires for participants, and quantitative outcome data collection of each intervention. Results: A total of 80 program activities (workshops and screening sessions) were conducted. Among the participants, 542 women and 30 men engaged in workshops. During the 30 Rapid Diagnostic Testing sessions, 150 individuals underwent testing for HIV, hepatitis B, and/or hepatitis C. Positivity rates were 6.7% for hepatitis B and 0.9% for hepatitis C. No HIV infections were detected. Participant satisfaction rates were consistently high (>76%) across workshops. Qualitative analysis unveiled two critical axes influencing program feasibility and effectiveness: program organization and CHW involvement. Discussion: This assessment of the program highlights its feasibility among a population that is difficult to reach through conventional healthcare efforts. The intervention's potential effectiveness is suggested by self- and CHW-reported improvements in sexual health literacy and high rates of referral to the healthcare system, as well as holistic well-being considerations. CHW involvement is a vital determinant of program success, as are robust coordination among stakeholders, deep understanding of the target population, and strong partner engagement. Conclusion: This outreach program amplifies the voices of often-overlooked populations while empowering them to navigate health and social challenges. Although these workshops serve as lifelines for those frequently excluded from mainstream services, long-term improvements to the health and wellbeing of homeless populations will necessitate systemic governmental intervention.
Asunto(s)
Infecciones por VIH , Hepatitis B , Hepatitis C , Salud Sexual , Masculino , Humanos , Femenino , Agentes Comunitarios de Salud , Paris , Servicios de Salud Comunitaria/métodos , Infecciones por VIH/prevención & control , Hepatitis B/prevención & controlRESUMEN
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B*15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B*15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the US (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B*15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified. These findings suggest that memory T-cell immunity to seasonal coronaviruses does not strongly influence the outcome of SARS-CoV-2 infection in unvaccinated individuals.
RESUMEN
BACKGROUND: Molnupiravir is an oral prodrug of ß-D-N4-hydroxycytidine, active against SARS-CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe-IN, a clinical trial evaluating molnupiravir in patients hospitalized with Covid-19. METHODS: We conducted a randomized, placebo-controlled, double-blind phase 2/3 trial in patients 18 years old and older requiring in-hospital treatment for laboratory-confirmed Covid-19 with symptom onset 10 or fewer days before randomization. Participants were randomly assigned to placebo or molnupiravir 200 mg, 400 mg, or 800 mg (1:1:1:1 ratio), twice daily for 5 days. Primary end points were safety and sustained recovery (participant alive and either not hospitalized or medically ready for discharge) through day 29. RESULTS: Of 304 randomly assigned participants, 218 received at least one dose of molnupiravir and 75 of placebo. At baseline, 74.0% had at least one risk factor for severe Covid-19. Adverse events were reported in 121 of 218 (55.5%) molnupiravir-treated and 46 of 75 (61.3%) placebo-treated participants, with no apparent dose effect on adverse event rates and no evidence of hematologic toxicity based on prespecified adverse events. Of 16 confirmed deaths, most were in participants with severe Covid-19 (75.0%), with underlying comorbidities (87.5%), older than 60 years of age (81.3%), and/or symptom duration longer than 5 days (75.0%) at randomization. Median time to sustained recovery was 9 days in all groups, with similar day 29 recovery rates ranging from 81.5% to 85.2%. CONCLUSIONS: In this phase 2 trial of patients hospitalized with Covid-19, a 5-day course of molnupiravir up to 800 mg twice daily was not associated with dose-limiting side effects or adverse events, but did not demonstrate clinical benefit. (Funded by Merck Sharp & Dohme; ClinicalTrials.gov NCT04575584.)
Asunto(s)
Antivirales , Tratamiento Farmacológico de COVID-19 , Citidina , Hospitalización , Hidroxilaminas , Humanos , Masculino , Persona de Mediana Edad , Femenino , Citidina/análogos & derivados , Citidina/uso terapéutico , Método Doble Ciego , Hidroxilaminas/uso terapéutico , Antivirales/uso terapéutico , Antivirales/efectos adversos , Antivirales/administración & dosificación , Anciano , Hospitalización/estadística & datos numéricos , Adulto , COVID-19 , SARS-CoV-2 , Resultado del TratamientoRESUMEN
OBJETIVOS: La eficacia de la profilaxis posexposición al virus de la inmunodeficiencia humana (VIH) depende de un tiempo inferior a 4 horas entre la exposición y la administración del tratamiento. Este estudio evalúa los factores predictores del tiempo entre la exposición al VIH y la llegada a urgencias. MÉTODOS: Estudio observacional, prospectivo, realizado en el Hospital Universitario de Bichat (París, Francia). Se incluyeron todas las consultas en urgencias en 2016 y 2017 por exposición al VIH -ocupacional y no ocupacional-. RESULTADOS: Se incluyeron 1.475 pacientes, de los que 598 completaron una encuesta de seguimiento. El retraso ($4horas) entre la exposición al VIH y la consulta en urgencias se asoció con el tipo de exposición al VIH: trabajadores sanitarios, otras exposiciones y sexuales (p < 0,001). Se encontraron diferencias entre la exposición sexual y otras: conocimiento del circuito de PEP: 65,2% y 46,9% (p < 0,001), uso previo de PEP: 23,9% y 13,1% (p = 0,001), uso de alcohol: 36,2% y 18,5% (p < 0,001), uso de drogas: 34,6% y 8,6% (p < 0,001), y chemsex: 26,1% y 0% (p < 0,001).En la exposición sexual, los siguientes factores predicen el retraso: conocimiento y uso previo del circuito de PEP(p < 0,001) disminuyen el riesgo de retraso > 4 horas, y uso de drogas (p = 0,03) y chemsex (p < 0,001) lo aumentan; en la exposición ocupacional, el conocimiento del programa PEP lo disminuye y el uso de drogas lo aumenta(p < 0,001). CONCLUSIÓN:El retraso en la consulta posexposición al VIH es mayor en la exposición sexual. El conocimiento del programa de PEP y su uso previo determinaban un retraso menor. En la exposición sexual, el consumo de alcohol, drogas y chemsex, implican un retraso mayor, en especial en hombres que tienen relaciones sexuales con hombres
BACKGROUND AND OBJECTIVE: The efficacy of postexposure prophylaxis (PEP) after human immunodeficiency virus (HIV)contact relies on administering the treatment within 4 hours of contact with the virus. This study aimed to evaluate predictors of the time that elapses between HIV exposure and emergency department arrival. METHODS: Prospective observational study carried out at Hôpital Bichat, a university teaching hospital in Paris, France. All emergency visits for occupational or non occupational exposure to HIV in 2016 and 2017 were included. RESULTS: A total of 1475 cases were studied; 598 patients responded to the follow-up survey. A delay of 4 hours or more between HIV exposure and the emergency department visit was associated with type of contact: health care occupational exposure, other occupational exposure, or sexual intercourse (P< .001). We found significant differences between individuals exposed during sexual contact versus occupational exposure with respect to knowledge of the PEP program pathway (65.2%vs 46.9%, respectively), previous use of PEP (23.9%vs 13.1%), alcohol intake (36.2%vs 18.5%), drug use (34.6%vs 8.6%), and chemsex (sexualized drug use) (26.1%vs 0%) (P< .001, all comparisons).Predictors of time until start of PEP among individuals exposed during sexual intercourse were knowledge and prioruse of the PEP pathway (P< .001), drug use (P= .03), and chemsex (P< .001). Predictors among occupationally exposed individuals were prior knowledge of the PEP pathway and drug use (P< .001). CONCLUSIONS: Delay in seeking PEP after HIV exposure is greater among individuals exposed during sexual intercourse. Knowledge of the PEP program and prior use of it are associated with less delay. Exposure during sexual intercourse, alcohol and drug use, and chemsex are associated with longer delays, especially in men who have sex with men